PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its participation in several major investor and healthcare conferences through November and December 2025, where company leadership will discuss ongoing progress across its autoimmune cell therapy pipeline.
The company will host a fireside chat at the TD Cowen Immunology & Inflammation Summit on Thursday, November 13, 2025, at 11:00 a.m. ET. Cabaletta will also appear at the Jefferies Global Healthcare Conference in London, holding a webcasted discussion on Monday, November 17, 2025, at 1:30 p.m. GMT.
In December, Cabaletta will participate in two additional high-profile investor events: the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on Tuesday, December 2, 2025, at 8:20 a.m. ET, and Citi’s 2025 Global Healthcare Conference in Miami, Florida, on Wednesday, December 3, 2025, at 1:45 p.m. ET.
Each session will include a live webcast accessible via the “News and Events” section of Cabaletta’s website, with replays available for 30 days following each event.
Cabaletta Bio, headquartered in Philadelphia, is a clinical-stage biotechnology company advancing what it describes as the first curative targeted cell therapies for autoimmune diseases. Its proprietary CABA™ platform supports the discovery and development of engineered T cell therapies designed to restore immune self-tolerance.
The company’s lead candidate, rese-cel — a 4-1BB-containing fully human CD19-CAR T cell investigational therapy — is being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical program, which spans multiple autoimmune disease areas, including rheumatology, neurology, and dermatology.
Cabaletta continues to position itself as a leader in next-generation autoimmune therapeutics, with its upcoming conference presentations expected to offer insight into both clinical progress and long-term strategy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.